A pilot study to examine the correlation between cognition and blood biomarkers in a Singapore Chinese male cohort with type 2 diabetes mellitus

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Goh, Deborah Amanda ^a   Dong, Yanhong ^a,b,c   Lee, Wah Yean ^a,b   Koay, Way Inn ^a,b   Tay, Stephen Ziyang ^a,b   Soon, Danny ^d   Chen, Christopher ^a,b   Brittain, Claire Frances ^e   Lowe, Stephen Loucian ^d   Wong, Boon Seng ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; LIPID;

ADULT; AGE DISTRIBUTION; ARTICLE; ATTENTION; BODY MASS; CASE CONTROL STUDY; CHINESE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COGNITION; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE DURATION; EDUCATION; EXECUTIVE FUNCTION; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; LANGUAGE; MALE; MENTAL PERFORMANCE; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; NON INSULIN DEPENDENT DIABETES MELLITUS; PILOT STUDY; SINGAPORE; TRIACYLGLYCEROL BLOOD LEVEL; VERBAL MEMORY; VISUAL MEMORY; VISUOMOTOR COORDINATION; BLOOD; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; EPIDEMIOLOGY; PATHOPHYSIOLOGY;

BIOLOGICAL MARKERS; COGNITION; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; EXECUTIVE FUNCTION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSULIN; LIPIDS; MALE; MIDDLE AGED; PILOT PROJECTS; SINGAPORE;

EID: 84901194848     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0096874     Document Type: Article

References (50)

1. Boyle JP, Thompson TJ, Gregg EW, Barker LE, Williamson DF (2010) Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr 8: 29.
2. Ramachandran A, Ma RC, Snehalatha C (2010) Diabetes in Asia. Lancet 375: 408-418.
3. Heng BH, Sun Y, Cheah JT, Jong M (2010) The Singapore National Healthcare Group Diabetes Registry - descriptive epidemiology of type 2 diabetes mellitus. Ann Acad Med Singapore 39: 348-352.
4. Taubes G (2003) Insulin insults may spur Alzheimer's disease. Science 301: 40-41.
5. Taubes G (2009) Insulin resistance. Prosperity's plague. Science 325: 256-260.
6. Stumvoll M, Goldstein BJ, van Haeften TW (2005) Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365: 1333-1346.
7. van Elderen SG, de Roos A, de Craen AJ, Westendorp RG, Blauw GJ, et al. (2010) Progression of brain atrophy and cognitive decline in diabetes mellitus: a 3-year follow-up. Neurology 75: 997-1002.
8. Logroscino G, Kang JH, Grodstein F (2004) Prospective study of type 2 diabetes and cognitive decline in women aged 70-81 years. Bmj 328: 548.
9. Okereke OI, Kang JH, Cook NR, Gaziano JM, Manson JE, et al. (2008) Type 2 diabetes mellitus and cognitive decline in two large cohorts of community-dwelling older adults. J Am Geriatr Soc 56: 1028-1036. (Pubitemid 351782711)
10. de la Monte SM, Wands JR (2005) Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. J Alzheimers Dis 7: 45-61.
11. Reger MA, Watson GS, Frey WH 2nd, Baker LD, Cholerton B, et al. (2006) Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging 27: 451-458. (Pubitemid 43185331)
12. Etgen T, Sander D, Bickel H, Sander K, F√αhrstl H (2010) Cognitive decline: the relevance of diabetes, hyperlipidaemia and hypertension. Br J Diabetes Vas Dis 10: 115-122.
13. Launer LJ (2009) Diabetes: vascular or neurodegenerative: an epidemiologic perspective. Stroke 40: S53-55.
14. Sims-Robinson C, Kim B, Rosko A, Feldman EL (2010) How does diabetes accelerate Alzheimer disease pathology? Nat Rev Neurol 6: 551-559.
15. Takeda S, Sato N, Uchio-Yamada K, Sawada K, Kunieda T, et al. (2010) Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci U S A 107: 7036-7041.
16. Mazzarella R, Schlessinger D (1998) Pathological consequences of sequence duplications in the human genome. Genome Res 8: 1007-1021. (Pubitemid 28532490)
17. Solomon A, Kareholt I, Ngandu T, Wolozin B, Macdonald SW, et al. (2009) Serum total cholesterol, statins and cognition in non-demented elderly. Neurobiol Aging 30: 1006-1009.
18. Chen CLH, Willis BA, Mooney L, Ong GK, Lim CN, et al. (2010) Cortisol response to individualised graded insulin infusions: a reproducible biomarker for CNS compounds inhibiting HPA activation. Br J Clin Pharmacol 70: 886-894.
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419. (Pubitemid 15018832)
20. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.
21. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, et al. (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53: 695-699. (Pubitemid 41623495)
22. Hachinski V, Iadecola C, Petersen RC, Breteler MM, Nyenhuis DL, et al. (2006) National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke 37: 2220-2241. (Pubitemid 44337162)
23. Marioni RE, Strachan MW, Reynolds RM, Lowe GD, Mitchell RJ, et al. (2010) Association between raised inflammatory markers and cognitive decline in elderly people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes 59: 710-713.
24. Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, et al. (2000) Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci 12: 233-239. (Pubitemid 30303778)
25. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, et al. (1982) Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 17: 37-49. (Pubitemid 13123113)
26. Hindmarch I, Lehfeld H, de Jongh P, Erzigkeit H (1998) The Bayer Activities of Daily Living Scale (B-ADL). Dement Geriatr Cogn Disord 9: 20-26. (Pubitemid 28325622)
27. SACMOT (2002) Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res 11: 193-205.
28. Deyo RA, Diehr P, Patrick DL (1991) Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation. Control Clin Trials 12: 142S-158S.
29. Zhong Y, Miao Y, Jia WP, Yan H, Wang BY, et al. (2012) Hyperinsulinemia, insulin resistance and cognitive decline in older cohort. Biomed Environ Sci 25: 8-14.
30. Yaffe K, Falvey C, Hamilton N, Schwartz AV, Simonsick EM, et al. (2012) Diabetes, glucose control, and 9-year cognitive decline among older adults without dementia. Arch Neurol 69: 1170-1175.
31. Euser SM, Sattar N, Witteman JC, Bollen EL, Sijbrands EJ, et al. (2010) A prospective analysis of elevated fasting glucose levels and cognitive function in older people: results from PROSPER and the Rotterdam Study. Diabetes 59: 1601-1607.
32. Zhou H, Lu W, Shi Y, Bai F, Chang J, et al. (2010) Impairments in cognition and resting-state connectivity of the hippocampus in elderly subjects with type 2 diabetes. Neurosci Lett 473: 5-10.
33. Wessels AM, Lane KA, Gao S, Hall KS, Unverzagt FW, et al. (2011) Diabetes and cognitive decline in elderly African Americans: a 15-year follow-up study. Alzheimers Dement 7: 418-424.
34. van den Kommer TN, Dik MG, Comijs HC, Fassbender K, Lutjohann D, et al. (2009) Total cholesterol and oxysterols: early markers for cognitive decline in elderly? Neurobiol Aging 30: 534-545.
35. Schreurs BG (2010) The effects of cholesterol on learning and memory. Neurosci Biobehav Rev 34: 1366-1379.
36. Benito-Leon J, Louis ED, Vega S, Bermejo-Pareja F (2010) Statins and cognitive functioning in the elderly: a population-based study. J Alzheimers Dis 21: 95-102.
37. Carlsson CM, Nondahl DM, Klein BE, McBride PE, Sager MA, et al. (2009) Increased atherogenic lipoproteins are associated with cognitive impairment: effects of statins and subclinical atherosclerosis. Alzheimer Dis Assoc Disord 23: 11-17.
38. Gillum RF, Obisesan TO (2011) Hgh-density lipoprotein cholesterol, cognitive function and mortality in a US National Cohort. Lipids in health and Disease 10: 26.
39. Atzmon G, Gabriely I, Greiner W, Davidson D, Schechter C, et al. (2002) Plasma HDL levels highly correlate with cognitive function in exceptional longevity. J Gerontol A Biol Sci Med Sci 57: M712-715. (Pubitemid 35340550)
40. Merched A, Xia Y, Visvikis S, Serot JM, Siest G (2000) Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer's disease. Neurobiol Aging 21: 27-30. (Pubitemid 30224782)
41. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, et al. (1989) High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79: 8-15. (Pubitemid 19043669)
42. Zhao WQ, Alkon DL (2001) Role of insulin and insulin receptor in learning and memory. Mol Cell Endocrinol 177: 125-134.
43. Thongtang N, Ai M, Otokozawa S, Himbergen TV, Asztalos BF, et al. (2011) Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation. Am J Cardiol 107: 387-392.
44. Sampson UK, Linton MF, Fazio S (2011) Are statins diabetogenic? Curr Opin Cardiol 26: 342-347.
45. Young SE, Mainous AG 3rd, Carnemolla M (2006) Hyperinsulinemia and cognitive decline in a middle-aged cohort. Diabetes Care 29: 2688-2693. (Pubitemid 44912200)
46. Mapous RL, Spector J (1995) Clinical neuropsychological assessment: A cognitive approach: Plenum Press. 362 p.
47. Bruce DG, Casey GP, Grange V, Clarnette RC, Almeida OP, et al. (2003) Cognitive impairment, physical disability and depressive symptoms in older diabetic patients: the Fremantle Cognition in Diabetes Study. Diabetes Res Clin Pract 61: 59-67. (Pubitemid 36808844)
48. Heianza Y, Hara S, Arase Y, Saito K, Fujiwara K, et al. (2011) HbA1c 5.7-6.4% and impaired fasting plasma glucose for diagnosis of prediabetes and risk of progression to diabetes in Japan (TOPICS 3): a longitudinal cohort study. Lancet 378: 147-155.
49. Cukierman-Yaffe T, Gerstein HC, Williamson JD, Lazar RM, Lovato L, et al. (2009) Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the action to control cardiovascular risk in diabetes-memory in diabetes (ACCORD-MIND) trial. Diabetes Care 32: 221-226.
50. Dong Y, Gan DZ, Tay SZ, Koay WI, Collinson SL, et al. (2013) Patterns of neuropsychological impairment in Alzheimer's disease and mixed dementia. J Neurol Sci 333: 5-8.